Literature DB >> 1529286

Measuring the quality of life of women with rheumatoid arthritis or systemic lupus erythematosus: a Swedish version of the Quality of Life Scale (QOLS).

C S Burckhardt1, B Archenholtz, A Bjelle.   

Abstract

The Quality of Life Scale (QOLS) was translated into Swedish and reliability and validity was studied. The Swedish version (QOLS-S) was given to 100 women with rheumatoid arthritis or systemic lupus erythematosus along with the Arthritis Impact Measurement Scales and a visual analog pain scale. Disease activity was also measured using the Ritchie Articular Index and a patient version of the Systemic Lupus Activity Measure. Results indicated that the QOLS-S had high test-retest reliability (r = .84 for a 4-week interval) and internal consistency reliability (alpha = .82 at Time 1 and .88 at Time 2). An hypothesis that the QOLS-S would have low to moderate correlations with measures of health status and disease activity was supported. We conclude that the QOLS-S is a reliable and valid measure of quality of life in Swedish women with RA and SLE and that it provides a measure of quality of life that is distinct from health status and disease activity.

Entities:  

Mesh:

Year:  1992        PMID: 1529286     DOI: 10.3109/03009749209099220

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  22 in total

Review 1.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Quality of life in patients with fibromyalgia: validation and psychometric properties of the German Quality of Life Scale (QOLS-G).

Authors:  Martin Offenbächer; Sebastian Sauer; Niko Kohls; Millard Waltz; Peter Schoeps
Journal:  Rheumatol Int       Date:  2011-10-30       Impact factor: 2.631

Review 3.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

4.  Health-related quality of life and employment among persons with systemic lupus erythematosus.

Authors:  Jinoos Yazdany; Edward Yelin
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

5.  The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis.

Authors:  A Wahl; T Moum; B R Hanestad; I Wiklund
Journal:  Qual Life Res       Date:  1999-06       Impact factor: 4.147

6.  Coping and quality of life in patients with psoriasis.

Authors:  A Wahl; B R Hanestad; I Wiklund; T Moum
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

7.  Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist.

Authors:  C Grootscholten; G Ligtenberg; R H W M Derksen; K M G Schreurs; J W de Glas-Vos; E C Hagen; A W L van den Wall Bake; T W J Huizinga; F H J van den Hoogen; M Bijl; J C van Houwelingen; F J Snoek; J H M Berden
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

8.  Validation and psychometric properties of the Spanish version of the Quality of Life Scale (QOLS) in patients with fibromyalgia.

Authors:  Pedro A Latorre-Román; Antonio Martínez-Amat; Emilio Martínez-López; Angel Moral; María A Santos; Fidel Hita-Contreras
Journal:  Rheumatol Int       Date:  2013-10-06       Impact factor: 2.631

9.  Two-year changes in quality of life in elderly patients with low-energy hip fractures. A case-control study.

Authors:  Gudrun Rohde; Glenn Haugeberg; Anne Marit Mengshoel; Torbjorn Moum; Astrid K Wahl
Journal:  BMC Musculoskelet Disord       Date:  2010-09-29       Impact factor: 2.362

10.  Quality of life in the general Norwegian population, measured by the Quality of Life Scale (QOLS-N).

Authors:  Astrid K Wahl; Tone Rustøen; Berit R Hanestad; Anners Lerdal; Torbjørn Moum
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.